We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Algorithm Predicts Prostate Cancer Recurrence in Patients Treated by Radiation Therapy

By MedImaging International staff writers
Posted on 02 Jan 2024
Print article
Image: The algorithm predicts prostate cancer recurrence 15 months faster in patients treated by radiation therapy (Photo courtesy of 123RF)
Image: The algorithm predicts prostate cancer recurrence 15 months faster in patients treated by radiation therapy (Photo courtesy of 123RF)

Radiation therapy is a prevalent treatment option for prostate cancer patients across various risk levels. Despite its effectiveness, 20% to 30% of patients will experience cancer recurrence within five years after treatment. Detecting this recurrence typically involves monitoring prostate-specific antigen (PSA) levels in the serum. However, this method can be slow, often delaying additional necessary treatments for those with returning tumors. Addressing this challenge, an international team of researchers has introduced a new patent-pending methodology and algorithm designed to predict the likelihood of prostate cancer recurrence post-radiation therapy.

Developed by specialists at Purdue University (West Lafayette, IN, USA), this innovative algorithm leverages data collected through routine patient monitoring. It is based on a patient-specific mechanistic model, which is continuously informed by periodic PSA measurements, a standard part of post-radiation monitoring for prostate cancer patients. The effectiveness of this approach was tested on historical data from 166 patients. For each patient, the algorithm's prediction of recurrence was compared with the actual occurrence as identified by traditional clinical practices. The findings were promising, indicating that the model-based predictors could flag potential relapses, on average, 14.8 months earlier than conventional methods. The researchers are now focusing on refining the model to benefit a broader range of patients.

“The PSA data is used in conjunction with the model to obtain patient-specific parameters that determine the PSA dynamics and serve as classifiers for recurrence,” said Hector Gomez, a professor at Purdue University. “In addition to recurrence identification, our model can be used for designing personalized PSA monitoring strategies. It can tell physicians the right time to investigate tumor recurrences and maximize the window of curability.”

“Our current model can be used only for patients who do not receive any treatment additional to radiation,” Gomez added. “Some patients receive radiation and hormone therapy simultaneously and cannot benefit from our method right now. We plan to extend the method to make it applicable also to patients who receive radiation and hormone therapy simultaneously.”

Related Links:
Purdue University

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
Fetal Monitor
Avante Compact II
New
Digital Radiography System
meX+20BT
New
Drape Barrier
Double Pivot Swing Arm Drape

Print article
Radcal

Channels

MRI

view channel
Image: The artificial intelligence model outperformed clinical tests at predicting the progress of Alzheimer’s disease (Photo courtesy of 123RF)

AI Outperforms Clinical Tests at Predicting Alzheimer’s Progress from MRI Scans

Dementia is a major global health challenge, impacting over 55 million individuals worldwide and costing approximately USD 820 billion annually. Projections indicate that the number of cases will nearly... Read more

Ultrasound

view channel
Image: The new FDA-cleared AI-enabled applications have been integrated into the EPIQ CVx and Affiniti CVx ultrasound systems (Photo courtesy of Royal Philips)

Next-Gen AI-Enabled Cardiovascular Ultrasound Platform Speeds Up Analysis

Heart failure is a significant global health challenge, affecting approximately 64 million individuals worldwide. It is associated with high mortality rates and poor quality of life, placing a considerable... Read more

General/Advanced Imaging

view channel
Image: The NeuroLF ultra-compact brain Positron Emission Tomography (PET) scanner (Photo courtesy of Positrigo)

Breakthrough Brain PET System Aids Diagnosis of Neurological Disorders

Alzheimer's disease (AD) is the most prevalent type of dementia, representing approximately 70% of all dementia cases in individuals over 60 years of age. As of 2020, there were more than 55 million people... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: Calantic Digital Solutions is an orchestrated suite of AI radiology solutions that aims to transform radiology (Photo courtesy of Bayer)

Bayer and Rad AI Collaborate on Expanding Use of Cutting Edge AI Radiology Operational Solutions

Imaging data constitutes approximately 90% of all medical data, with the volume of such data continuously expanding, thereby significantly increasing the workload for radiologists amid existing resource limitations.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.